Targets › KMT2A
3 programs from 3 companies in 15 trials: 11 Phase 1, 2 Phase 3, 2 Phase 2; Oncology; next expected readout Dec 2026.
Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). (UniProt, Q03164)
Open in Phaseline: the race on KMT2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals | revumenib Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor | MEN1, KMT2A | Phase 3 | Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage … | Feb 2027 |
| M.D. Anderson Cancer Center | Revumenib Sesquifumarate (SNDX-5613) Menin/Histone-lysine N-methyltransferase MLL inhibitor | MEN1, KMT2A | Phase 2 | Leukemia; Acute Myeloid Leukemia | Dec 2026 |
| The First Affiliated Hospital of Soochow University | BY002 Menin inhibitor targeting KMT2A-rearranged and NPM1-mutant acute leukemia | KMT2A, MENIN | Phase 1 | Acute Leukemia | Mar 2027 |
Acute Myeloid Leukemia (5) Acute Myeloid Leukemias (2) Acute Leukemia (2) Leukemia (2) Acute Myeloid Leukemia, Adult (1) Recurrent Acute Leukemia of Ambiguous Lineage (1) Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia With FLT3/ITD Mutation (1)
small molecule (3)
Syndax Pharmaceuticals (1) M.D. Anderson Cancer Center (1) The First Affiliated Hospital of Soochow University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.